Creating new antimicrobial drugs will require governments working with industry
The pharmaceutical industry has demonstrated its willingness to take on the risk and uncertainty that come with trying to develop medicines that address unmet needs. When it comes to antimicrobial drugs, the hurdle is not that the risks are too high, it is that the rewards are too low. The big question is this: What is society as whole ready to invest to avoid a post-antibiotic era?
OUR UNDERWRITERS
Unrestricted financial support by:
 |
Antimicrobial Resistance Fighter Coalition |
 |
Bangalore Bioinnovation Centre |
 |
INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS |
 |
BD |
AMR NEWS
Your Biweekly Source for Global AMR Insights!
Stay informed with the essential newsletter that brings together all the latest One Health news on antimicrobial resistance. Delivered straight to your inbox every two weeks, AMR NEWS provides a curated selection of international insights, key publications, and the latest updates in the fight against AMR.
Don’t miss out on staying ahead in the global AMR movement—subscribe now!
